Kura Oncology (NASDAQ:KURA) Price Target Raised to $37.00

Kura Oncology (NASDAQ:KURA) had its price objective hoisted by equities research analysts at HC Wainwright from $32.00 to $37.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 132.56% from the company’s current price.

Several other analysts have also recently weighed in on the stock. JMP Securities restated a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Tuesday. UBS Group began coverage on Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price target on the stock. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday. Wedbush reiterated an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research report on Monday, November 4th. Finally, Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and dropped their target price for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and an average target price of $29.67.

Kura Oncology Trading Down 0.3 %

Shares of KURA opened at $15.91 on Thursday. Kura Oncology has a 1-year low of $9.06 and a 1-year high of $24.17. The company has a market capitalization of $1.24 billion, a P/E ratio of -6.74 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The firm’s 50 day simple moving average is $18.28 and its 200 day simple moving average is $19.82.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors have recently bought and sold shares of KURA. SG Americas Securities LLC bought a new stake in Kura Oncology in the first quarter valued at approximately $110,000. ProShare Advisors LLC increased its stake in shares of Kura Oncology by 9.7% in the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after buying an additional 1,588 shares during the period. Vanguard Group Inc. raised its holdings in Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after buying an additional 28,212 shares during the last quarter. Avoro Capital Advisors LLC boosted its position in Kura Oncology by 29.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after buying an additional 870,000 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Kura Oncology by 17.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock worth $430,000 after acquiring an additional 2,940 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.